Alembic Pharmaceuticals receives EIR from USFDA on new Injectable Facility (F-3) at Karakhadi

Alembic added, "USFDA has also indicated that a compliance verification would be performed during re-inspection of the said Facility in the next review cycle."

Oct 12, 2021 03:10 IST India Infoline News Service

Alembic Pharmaceuticals
Alembic Pharmaceuticals has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by the regulator at the company's New Injectable Facility (F-3) at Karakhadi.

In its regulatory filing, Alembic said that "the Company has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out by them at our New Injectable Facility (F-3) at Karakhadi during the period from 28th January 2021 to 5th February 2021, indicating that the USFDA finds our responses to their observations to be adequate."

Further, Alembic added, "USFDA has also indicated that a compliance verification would be performed during re-inspection of the said Facility in the next review cycle."

At around 2.59 pm, Alembic was trading at Rs825 per piece up 0.7% on Sensex. The stock has touched an intraday high and low of Rs863.10 per piece and Rs818.55 per piece respectively. 

Related Story

Open Free Demat Account (Rs699)
Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity